You are here :
Moneycontrol »
Markets » Profit & Loss account - GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals
BSE: 500660 | NSE: GLAXO | ISIN: INE159A01016 | Pharmaceuticals
Profit & Loss account of GlaxoSmithKline Pharmaceuticals |
------------------- in Rs. Cr. ------------------- |
|
Dec '04 |
Dec '05 |
Dec '06 |
Dec '07 |
Dec '08 |
 |
|
12 mths |
12 mths |
12 mths |
12 mths |
12 mths |
|
| Income |
|
|
|
|
| Sales Turnover |
1,483.83 |
1,579.58 |
1,681.07 |
1,721.12 |
1,762.64 |
| Excise Duty |
116.11 |
105.51 |
139.14 |
142.54 |
86.28 |
| Net Sales |
1,367.72 |
1,474.07 |
1,541.93 |
1,578.58 |
1,676.36 |
| Other Income |
135.93 |
262.55 |
254.01 |
241.51 |
216.03 |
| Stock Adjustments |
3.18 |
-0.54 |
22.58 |
-16.80 |
2.33 |
| Total Income |
1,506.83 |
1,736.08 |
1,818.52 |
1,803.29 |
1,894.72 |
| Expenditure |
|
|
|
|
| Raw Materials |
596.90 |
637.26 |
651.18 |
616.40 |
653.26 |
| Power & Fuel Cost |
16.47 |
16.61 |
19.23 |
20.54 |
24.75 |
| Employee Cost |
168.51 |
156.06 |
153.87 |
151.45 |
173.05 |
| Other Manufacturing Expenses |
27.93 |
28.97 |
40.35 |
43.33 |
46.55 |
| Selling and Admin Expenses |
161.70 |
167.56 |
143.93 |
136.31 |
140.68 |
| Miscellaneous Expenses |
34.34 |
44.37 |
43.80 |
12.27 |
12.27 |
| Preoperative Exp Capitalised |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total Expenses |
1,005.85 |
1,050.83 |
1,052.36 |
980.30 |
1,050.56 |
|
Dec '04 |
Dec '05 |
Dec '06 |
Dec '07 |
Dec '08 |
|
|
12 mths |
12 mths |
12 mths |
12 mths |
12 mths |
|
| Operating Profit |
365.05 |
422.70 |
512.15 |
581.48 |
628.13 |
| PBDIT |
500.98 |
685.25 |
766.16 |
822.99 |
844.16 |
| Interest |
1.88 |
1.67 |
1.35 |
1.35 |
0.53 |
| PBDT |
499.10 |
683.58 |
764.81 |
821.64 |
843.63 |
| Depreciation |
17.47 |
15.73 |
15.85 |
16.16 |
16.34 |
| Other Written Off |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Profit Before Tax |
481.63 |
667.85 |
748.96 |
805.48 |
827.29 |
| Extra-ordinary items |
3.66 |
5.84 |
6.70 |
-38.87 |
0.50 |
| PBT (Post Extra-ord Items) |
485.29 |
673.69 |
755.66 |
766.61 |
827.79 |
| Tax |
152.19 |
171.62 |
194.23 |
211.46 |
231.54 |
| Reported Net Profit |
333.09 |
502.08 |
545.51 |
537.66 |
576.57 |
| Total Value Addition |
408.96 |
413.57 |
401.18 |
363.90 |
397.31 |
| Preference Dividend |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Equity Dividend |
209.57 |
237.17 |
262.58 |
304.93 |
338.81 |
| Corporate Dividend Tax |
27.39 |
33.26 |
36.83 |
51.82 |
57.58 |
| Per share data (annualised) |
|
|
|
|
| Shares in issue (lakhs) |
873.23 |
847.03 |
847.03 |
847.03 |
847.03 |
| Earning Per Share (Rs) |
38.15 |
59.28 |
64.40 |
63.48 |
68.07 |
| Equity Dividend (%) |
240.00 |
280.00 |
310.00 |
360.00 |
400.00 |
| Book Value (Rs) |
105.84 |
111.99 |
141.05 |
160.67 |
181.94 |
|
|
|
|
| Source : Religare Technova |
| Explore GlaxoSmithKline connections |
|
